Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

This study was terminated after 60 weeks due to the commercial availability of valbenazine.

Inclusion Criteria:

- Have participated in and completed the NBI-98854-1304 (Kinect 3) or NBI-98854-1402
(Kinect 4) Phase 3 study.

- Participants of childbearing potential must agree to use hormonal or two forms of
nonhormonal contraception (dual contraception) consistently throughout the study and
until 30 days after the last dose of valbenazine.

- If using maintenance medication(s) for schizophrenia or schizoaffective disorder, mood
disorder, or other conditions, be on stable doses.

- Be in general good health.

- Have adequate hearing, vision, and language skills to perform the procedures specified
in the protocol.

Exclusion Criteria:

- Have an active, clinically significant unstable medical condition within 1 month prior
to screening.

- Have a known history of substance dependence, substance (drug) or alcohol abuse.

- Have a significant risk of suicidal or violent behavior.

- Have a known history of neuroleptic malignant syndrome.

- Have a known history of long QT syndrome or cardiac arrhythmia.

- Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed).

- Have received an investigational drug within 30 days before screening or plan to use
an investigational drug (other than valbenazine) during the study.

- Have a blood loss ≥550 mL or donated blood within 30 days prior to Baseline.

- Have an allergy, hypersensitivity, or intolerance to tetrabenazine.

- Are currently pregnant or breastfeeding.